Država: Velika Britanija
Jezik: angleščina
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Codeine phosphate; Paracetamol
Zentiva Pharma UK Ltd
N02AJ06
Codeine phosphate; Paracetamol
30mg ; 500mg
Oral tablet
Oral
Schedule 5 (CD Inv)
Valid as a prescribable product
BNF: 04070100; GTIN: 5000283607069
OBJECT 1 CO-CODAMOL 30/500 TABLETS Summary of Product Characteristics Updated 11-Jan-2017 | Zentiva 1. Name of the medicinal product Co-codamol 30/500 Tablets. 2. Qualitative and quantitative composition Each tablet contains 500mg paracetamol and 30mg codeine phosphate hemihydrate. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Tablet White capsule-shaped tablets, marked SOLPADOL on one side. 4. Clinical particulars 4.1 Therapeutic indications For the relief of severe pain. Codeine is indicated in patients older than 12 years of age for the treatment of acute moderate pain which is not considered to be relieved by other analgesics such as paracetamol or ibuprofen (alone). 4.2 Posology and method of administration POSOLOGY Adults: Two tablets not more frequently than every 4 hours, up to a maximum of 8 tablets in any 24 hour period. Elderly: As for adults, however a reduced dose may be required. See warnings. Children aged 16 to 18 years: One to two tablets every 6 hours when necessary to up a maximum of 8 tablets in 24 hours. Children aged 12 to 15 years: One tablet every 6 hours when necessary to a maximum of 4 tablets in 24 hours. Do not take for more than 3 days without consulting your doctor. PAEDIATRIC POPULATION Children aged less than 12 years: Codeine should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see section 4.3 and 4.4). METHOD OF ADMINISTRATION For oral administration. 4.3 Contraindications • Hypersensitivity to the active substances or any of the other excipients listed in Section 6.1. • Conditions where morphine and opioids are contraindicated e.g., acute asthma, respiratory depression, acute alcoholism, head injuries, raised intra-cranial pressure and following biliary tract surgery; monoamine oxidase inhibitor therapy, concurrent or within 14 days. • In all paediatric patients (0-18 years of age) who undergo tonsillectomy and/or adenoidectomy for Preberite celoten dokument